Interleukin 1 Alpha Gene Polymorphism in Breast Cancer After Chemotherapy Treatment

Abstract

Abstract Background: The interleukin 1 (IL-1) family of cytokines is essential for triggering and controlling immunological and inflammatory responses. We believe the levels of these cytokines in breast tumor homogenates relate to other known prognosticators of patient survival. Objectives: The association between the risk of breast tumors and the IL-1 alpha −889 C>T Promoter Primer polymorphism has been established. Interleukin 1 alpha −889 C>T Promoter Primer has been proven to influence breast tumor susceptibility. Our research aimed to determine whether the IL-1 alpha −889 C>T Promoter Primer gene polymorphism and susceptibility to Breast cancers (BCs) are related. Materials and Methods: The genotype frequencies of the IL-1 alpha −889 C>T Promoter Primer polymorphism were compared between 100 BC cases and 50 controls with the assistance of polymerase chain reaction and restriction fragment length polymorphism techniques. Additional multivariate binary logistic regression analyses were carried out to determine the level of IL-1 in patients’ blood and to examine the association between the IL-1 alpha −889 C>T Promoter Primer polymorphism and BC risk utilizing the ELISA technique after therapy. Results: The concentration of CA 15-3 in patients with BC was 101.107 increase significantly compare with mean of control group was 62.802, in chemotherapy patients genotype frequencies of TT, CT, CC of IL-1 alpha −889 C>T gene polymorphism where it patients with genotype TT were affected by breast tumors approximately one time comparison with patients having genotype CT (odd ratio = 1.50 and 0.91). Conclusion: Concentration of CA 15-3 increase in patients after chemotherapy compared with healthy, The IL-1 alpha −889 C>T polymorphism affects breast tumors in women.